Abstract
Selective inhibitors of the Src family of protein tyrosine kinases have been developed as therapeutic agents for human tumors, some of which are now in various stages of clinical trial. In this review, recently described novel small molecule ATP-competitive Src inhibitors are discussed, with an emphasis on their potential use as therapeutic inhibitors for advanced-stage malignancies.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Antineoplastic Agents / chemistry*
-
Antineoplastic Agents / therapeutic use*
-
Humans
-
Neoplasms / drug therapy*
-
Neoplasms / enzymology
-
Protein Kinase Inhibitors / chemistry*
-
Protein Kinase Inhibitors / therapeutic use*
-
src-Family Kinases / antagonists & inhibitors*
-
src-Family Kinases / chemistry
-
src-Family Kinases / metabolism
Substances
-
Antineoplastic Agents
-
Protein Kinase Inhibitors
-
src-Family Kinases